Home

search

Subjectguide
Journals
Books / Serials / Multimedia
Services
Services

Login for Subscribers
Logout

Sitemap
Help
Contacts


Logo






Vol. 71, No. 1, 2005   

Free Abstract     Article (Fulltext)     Article (PDF 151 KB)     

Review

Extraintestinal Manifestations of Crohn's Disease
Pascal Juillerata, Christian Motteta, Florian Froehlicha, b, Christian Felleya, John-Paul Vaderc, Bernard Burnandc, Jean-Jacques Gonversa, Pierre Michettia

aDivision of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne;
bGastrointestinal Department, University of Basle, Basle, and
cInstitute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland

Address of Corresponding Author

Digestion 2005;71:31-36 (DOI: 10.1159/000083870)


 goto top of page Key Words

  • Crohn's disease
  • Inflammatory bowel disease
  • Extraintestinal manifestations
  • Ankylosing spondylitis
  • Pyoderma gangrenosum
  • Primary sclerosing cholangitis
  • Uveitis
  • Extraintestinal manifestations of CD, treatment

 goto top of page Abstract

In each case of extraintestinal manifestations of Crohn's disease, active disease, if present, should be treated to induce remission, which may positively influence the course of most concomitant extraintestinal manifestations. For some extraintestinal manifestations, however, a specific treatment should be introduced. This latter part of disease management will be discussed in this chapter, in particular for pyoderma gangrenosum, uveitis, spondylarthropathy - axial arthropathy - and primarysclerosing cholangitis, which have also been described in quiescent Crohn's disease. Few new drugs for the treatment of extraintestinal manifestations of Crohn's disease have been developed in the past and only the role of infliximab has increased in Crohn's disease-related extraintestinal manifestations. Drugs specifically aimed at this treatment, stemming from a few randomized controlled studies or case series, are sulfasalazine, 5-ASA, corticosteroids, azathioprine or 6-mercaptopurine, methotrexate, infliximab, dapsone and cyclosporine or tacrolimus.

Copyright © 2005 S. Karger AG, Basel


 goto top of page Author Contacts

Pierre Michetti, MD
Division of Gastroenterology and Hepatology
Lausanne University Medical Center
Rue du Bugnon 46, CH-1011 Lausanne (Switzerland)
Tel. +41 21 3140690, Fax +41 21 3140707, E-Mail Pierre.Michetti@hospvd.ch


 goto top of page Article Information

Published online: February 4, 2005
Number of Print Pages : 6
Number of Figures : 0, Number of Tables : 0, Number of References : 86

 
Journal Home
Journal Content
Guidelines
Editorial Board
Aims and Scope
Subscriptions
Medline Abstract (ID 15711047)
Download Citation
Cited In



This journal is part of the third subject package of the Karger

Journal Archive Collection

Information on packages (PDF)
Free sample issues

Case Reports in Gastroenterology


For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.





copyright  © 2009 S. Karger AG, Basel